Carole S. Ben-Maimon
CEO & DirectorDr. Carole S. Ben-Maimon, M.D., is Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020 and was its President. She was Chief Executive Officer, President and Director at Chondrial Therapeutics LLC since December 2016 until May 28, 2020. Dr. Ben-Maimon served as the President of Global Pharmaceuticals Division at Impax Laboratories Inc. from September 6, 2011 to November 3, 2014. Dr. Ben-Maimon served as the Founder, President and Chief Executive Officer of Alita Pharmaceuticals, Inc. from September 2006 to June 2009. Dr. Ben-Maimon served as the President and Chief Operating Officer of Duramed Research Inc. Prior thereto and from 2014 to 2016, she served as an independent consultant at CSGB Consulting, LLC. She joined Barr in 2001 where she was responsible for recruiting industry-leading talent and developing a pipeline of near and mid-term brand pharmaceutical products. During her tenure, Dr. Ben-Maimon was responsible for FDA approval and launch of the industry’s first extended cycle oral contraceptive and for the approval and launch of the second generation of extended cycle oral contraceptives. Dr. Ben-Maimon served as the Senior Vice President for Science & Public Policy for Teva Pharmaceuticals USA from 2000 to 2001, Senior Vice President, Research and Development, from 1996 to 2000 and Vice President, Medical and Regulatory Affairs, with Lemmon Company (a wholly owned subsidiary of Teva Pharmaceuticals, Inc.) from 1993 to 1996. During her seven-year tenure with Teva, she managed the development of more than 30 products. She served as Senior Vice President of Teva Branded Pharmaceutical Products R&D, Inc. since December 2003 and served as its Chief Operating Officer and President - Barr Research. She has experience in the pharmaceutical industry, having held various senior leadership positions at Impax Laboratories, Inc., Qualitest Pharmaceuticals, Inc., Barr Pharmaceuticals, Inc., including Duramed Research Inc. (a wholly owned subsidiary of Barr Pharmaceuticals, Inc.) and with Teva Pharmaceuticals USA. Dr. Ben-Maimon was with Wyeth Ayerst. Dr. Ben-Maimon has extensive experience in drug development and commercialization. Her experience includes the leadership of multi-disciplinary teams supporting the development of drugs and biologics in many therapeutic categories including CNS, women’s health, OTC-switch, urology, gastroenterology and vaccines. She served as the Chairman of the Board at Bionpharma Inc. and serves as its Director. From 1999 to 2002, she served as the Chairman of the Generic Pharmaceutical Association (GPhA) and frequently advocated for industry issues in both the federal and state political arenas. She serves as a Trustee of Albert Einstein Healthcare Network. She served as Senior Vice President, Corporate Strategy, at Qualitest Pharmaceuticals, Incorporatedfrom July 2009 to July 2010. She has also served on the Board of Directors of Barr Pharmaceuticals from 2001 to 2006. She has been a Member of Ideation Advisory Board at Banner Life Sciences, LLC. She served as a Director of Alita Pharmaceuticals, Inc. from September 2006 to June 2009. She served as a Director of Association for Accessible Medicines (a/k/a Generic Pharmaceutical Association). She served as a Director at Teva Branded Pharmaceutical Products R&D, Inc., since February 2001. She served as a Director of Impax Laboratories Inc. She serves as an Independent Director of Teligent, Inc. since March 31, 2016. She is Board Certified in Internal Medicine. She is a published author of numerous scientific and clinical articles. She completed clinical and research training in Nephrology at Thomas Jefferson University. Dr. Ben-Maimon is a Magna Cum Laude graduate of Thomas Jefferson Medical College and received her B.A. in biology from The University of Pennsylvania.
Positions
- Company NameLarimar Therapeutics, Inc.Stock CodeLRMRPositionCEO & DirectorColleagues
- JTJoseph TruittIndependent Chairman of the Board
- MCMichael CelanoSecretary & CFO
- GSGopi ShankarChief Development Officer
- JBJohn B. HarlowPresident & COO
- JBJohn BermanVice President of Finance & Administration
- JSJonathan S. LeffIndependent Director
- FEFrank Edward ThomasIndependent Director
- TEThomas Edward HamiltonIndependent Director
